165 related articles for article (PubMed ID: 36061157)
41. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
42. Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
Albandar HJ; Fuqua J; Albandar JM; Safi S; Merrill SA; Ma PC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33673446
[TBL] [Abstract][Full Text] [Related]
43. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
[TBL] [Abstract][Full Text] [Related]
44. Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.
Hashash JG; Francis FF; Farraye FA
Gastroenterol Hepatol (N Y); 2021 Aug; 17(8):358-366. PubMed ID: 34602898
[No Abstract] [Full Text] [Related]
45. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
46. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
47. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
Luo J; Beattie JA; Fuentes P; Rizvi H; Egger JV; Kern JA; Leung DYM; Lacouture ME; Kris MG; Gambarin M; Santomasso BD; Faleck DM; Hellmann MD
J Thorac Oncol; 2021 Oct; 16(10):1759-1764. PubMed ID: 34265432
[TBL] [Abstract][Full Text] [Related]
48. Gastrointestinal Tract Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
[TBL] [Abstract][Full Text] [Related]
49. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Shi Y; Fang J; Zhou C; Liu A; Wang Y; Meng Q; Ding C; Ai B; Gu Y; Yao Y; Sun H; Guo H; Zhang C; Song X; Li J; Xu B; Han Z; Song M; Tang T; Chen P; Lu H; Shui Y; Lou G; Zhang D; Liu J; Liu X; Liu X; Gao X; Zhou Q; Chen M; Zhao J; Zhong W; Xu Y; Wang M
Thorac Cancer; 2022 Feb; 13(3):412-422. PubMed ID: 34935288
[TBL] [Abstract][Full Text] [Related]
50. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
51. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.
Jacob JS; Dutra BE; Garcia-Rodriguez V; Panneerselvam K; Abraham FO; Zou F; Ma W; Grivas P; Thompson JA; Altan M; Oliva ICG; Zhang HC; Thomas AS; Wang Y
J Natl Compr Canc Netw; 2021 Aug; 19(12):1415-1424. PubMed ID: 34348238
[TBL] [Abstract][Full Text] [Related]
52. Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies.
Iivanainen S; Ekstrom J; Virtanen H; Kataja VV; Koivunen JP
BMC Med Inform Decis Mak; 2021 Jun; 21(1):205. PubMed ID: 34193140
[TBL] [Abstract][Full Text] [Related]
53. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
54. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
55. Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience.
Parente P; Maiorano BA; Ciardiello D; Cocomazzi F; Carparelli S; Guerra M; Ingravallo G; Cazzato G; Carosi I; Maiello E; Bossa F
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328239
[No Abstract] [Full Text] [Related]
56. Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department.
Castillo RM; Sandefur BJ; Finch AS; Richter MD; Thanarajasingam U
Mayo Clin Proc Innov Qual Outcomes; 2021 Dec; 5(6):1029-1035. PubMed ID: 34765885
[TBL] [Abstract][Full Text] [Related]
57. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
[TBL] [Abstract][Full Text] [Related]
58. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
[TBL] [Abstract][Full Text] [Related]
60. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
